<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842736</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-0101</org_study_id>
    <nct_id>NCT02842736</nct_id>
  </id_info>
  <brief_title>A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding</brief_title>
  <acronym>CLARITY</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Channel Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Channel Medsystems</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of the Cerene
      Cryotherapy Device in reducing menstrual bleeding in women with heavy menstrual bleeding
      (menorrhagia) due to benign causes for whom child bearing is complete.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Incidence of serious adverse events and serious device-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of serious adverse events and serious device-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint: Reduction in menstrual bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in menstrual bleeding</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Endometrial Cryoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cerene(TM) Cryotherapy Device</intervention_name>
    <arm_group_label>Endometrial Cryoablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory heavy menstrual bleeding with no definable organic cause

          -  Female subject age 25 to 50 years, inclusive

          -  Sounded length of uterine cavity no greater than 10 cm and endometrial cavity no
             greater than 6.5 cm

          -  Sufficient myometrial thickness

          -  Documented excessive menstrual blood loss within 3 months of informed consent

          -  Premenopausal confirmed by follicle stimulating hormone (FSH) measurement

          -  Agrees to use a reliable form of contraception following ablation treatment

          -  Provides written informed consent using a form that has been approved by the reviewing
             ethics committee

          -  Agrees to follow-up exams and data collection requirements

          -  Demonstrates an understanding of how to record menstrual blood loss using a menstrual
             pictogram

          -  Has predictable, cyclic menstrual cycles

        Exclusion Criteria:

          -  Pregnant or has a desire to conceive

          -  Endometrial hyperplasia as confirmed by histology

          -  Active endometritis

          -  Active pelvic inflammatory disease

          -  Active sexually transmitted disease (STD)

          -  Presence of bacteremia, sepsis, or other active systemic infection

          -  Active infection of the genitals, vagina, cervix, or uterus

          -  Known/suspected abdominal, pelvic, or gynecological malignancy within the past 5 years

          -  Known clotting defects or bleeding disorders

          -  Abnormal cytology on Human papillomavirus (HPV) testing not treated according to local
             standards.

          -  Prior uterine surgery that interrupts the integrity of the uterine wall (e.g.,
             transmural myomectomy or classical cesarean section).

          -  Previous low transverse cesarean section where the myometrial wall thickness is
             insufficient

          -  Previous endometrial ablation procedure

          -  Clinically significant adenomyosis indicated by subject complaints, imaging, or
             clinician's judgment

          -  Presence of an implantable contraceptive device

          -  Currently on medications that could thin the myometrial muscle

          -  Currently on anticoagulants

          -  Abnormal or obstructed cavity

          -  Currently using an intrauterine device (IUD) and unwilling to remove the IUD

          -  Post-partum ≤ 6-months

          -  Considering participation in a research study of an investigational drug or device
             that would begin during the course of this investigational study

          -  Any general health or mental, or other situation or condition which, in the opinion of
             the Investigator, could represent an increased risk for the subject or impact the
             subject's ability to comply with protocol requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WomanCare PC</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Advance Gynecologic Surgery Institute</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basinski LLC</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Women's Medical Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seven Hills Women's Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amy Brenner MD and Associates, LLC</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2J 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaSalle Hospital</name>
      <address>
        <city>Lasalle</city>
        <state>Quebec</state>
        <zip>H8P 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Universidad Autónoma de Nuevo Leon</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>66460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heavy menstrual bleeding</keyword>
  <keyword>endometrial ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

